July 9, 2008 - GlobeImmune, Inc. announced the signing of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) at the National Institutes of Health (NIH) to jointly develop products intended to treat a variety of cancers. GlobeImmune will utilize its proprietary Tarmogen® technology to develop multiple immunotherapy products expressing various cancer antigens provided by the NIH and the NIH will conduct and fund preclinical and early clinical development of the product candidates. Dr. Jeffrey Schlom, Chief of the Laboratory of Tumor Immunology and Biology at the NCI, will be the principal investigator for these studies. CEA (carcinoembryonic antigen), the first cancer antigen to be evaluated in this collaboration, is over-expressed in a number of human cancers, including over 90% of gastrointestinal cancers (colorectal, pancreas), 70% of non-small cell lung cancers (NSCLC) and 50% of breast cancers. Dr. Schlom’s group has already published two manuscripts from the NCI-GlobeImmune preclinical collaboration (Bernstein et al, Vaccine (2008) 26, 509-521; and Wansley et al, Clinical Cancer Research; July 1, 2008). Preclinical studies performed by Dr. Schlom’s group may be translated into NCI-funded clinical programs with promising Tarmogen candidates... GlobeImmune's Press Release -
Showing posts with label GlobeImmune. Show all posts
Showing posts with label GlobeImmune. Show all posts
Aug 4, 2008
GlobeImmune : CRADA with the National Institutes of Health to Develop Cancer Therapeutics
July 9, 2008 - GlobeImmune, Inc. announced the signing of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) at the National Institutes of Health (NIH) to jointly develop products intended to treat a variety of cancers. GlobeImmune will utilize its proprietary Tarmogen® technology to develop multiple immunotherapy products expressing various cancer antigens provided by the NIH and the NIH will conduct and fund preclinical and early clinical development of the product candidates. Dr. Jeffrey Schlom, Chief of the Laboratory of Tumor Immunology and Biology at the NCI, will be the principal investigator for these studies. CEA (carcinoembryonic antigen), the first cancer antigen to be evaluated in this collaboration, is over-expressed in a number of human cancers, including over 90% of gastrointestinal cancers (colorectal, pancreas), 70% of non-small cell lung cancers (NSCLC) and 50% of breast cancers. Dr. Schlom’s group has already published two manuscripts from the NCI-GlobeImmune preclinical collaboration (Bernstein et al, Vaccine (2008) 26, 509-521; and Wansley et al, Clinical Cancer Research; July 1, 2008). Preclinical studies performed by Dr. Schlom’s group may be translated into NCI-funded clinical programs with promising Tarmogen candidates... GlobeImmune's Press Release -
Mar 21, 2008
GlobeImmune, Initiation of a Phase 2a Clinical Trial of GI-4000 in Patients with Non-Small Cell Lung Cancer
March 19, 2008 - GlobeImmune, Inc. announced the initiation of a Phase 2a clinical trial at Memorial Sloan Kettering Cancer Center (MSKCC) to evaluate GlobeImmune’s GI-4000 Tarmogen® for the treatment of non-small cell lung cancer (NSCLC) patients with tumors having mutations in the ras gene.Molecular profiling of NSCLC tumors :
“NSCLC patients with tumors positive for mutated ras have a worse survival compared to patients with other NSCLC types in the setting of traditional therapy," said Dr. Christopher G. Azzoli, Principal Investigator for the Phase 2a study at MSKCC. "Furthermore, these patients may not benefit from treatment with selective tyrosine kinase inhibitors. Better treatments for lung cancer with mutated ras are greatly needed... GlobeImmune's Press Release -
Subscribe to:
Comments (Atom)
